EUCTR2005-004605-29-ITActive, not recruitingNot Applicable
A Phase IIIb Study of Tarceva (Erlotinib) in patients with locally advanced, unresectable or metastatic pancreatic cancer - TARCEVA - EAP in pancreatic carcinoma
Conditions
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- ROCHE
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •- Histologically or cytologically confirmed pancreatic cancer (adenocarcinoma), with measurable or non measurable locally advanced, unresectable (stage III) or metastatic pancreatic cancer (stage IV) disease (according to TNM 6th edition). - No prior systemic treatment for metastatic pancreatic cancer is allowed. Radiotherapy (adjuvant setting with ≤ 350 mg/m2/week gemcitabine) is allowed if progressive lesion(s) present outside the irradiated port. All adjuvant therapy will have been given at least 6 months prior to study entry and patients must have fully recovered from their adjuvant therapy toxicity. - Age ≥ 18 years - ECOG performance status of 0 - 3 - Life expectancy of at least 12 weeks - Granulocyte count > 1.5 x 109/L and platelet count > 100 x 109/L - Serum (total) bilirubin ≤ 1.5 x ULN, AST & ALT ≤ 2.5 x ULN ( ≤ 5 x ULN in patients with liver metastases) - Alk Phos ≤ 2.5 ULN. If Alk Phos is ≥ 2.5 ULN, SGOT (AST) and SGPT (ALT) must be ≤ 1.5 ULN (or <5 ULN in case of liver metastases). - Serum creatinine < 1.5 ULN or creatinine clearance > 60 ml/min - Able to comply with study and follow-up procedures - For all females of childbearing potential a negative pregnancy test must be obtained within 72 hours before starting therapy. - Patients with reproductive potential must use effective contraception - Written (signed) Informed Consent to participate in the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •- Any unstable systemic disease (including active infection, grade 4 hypertension, unstable angina, congestive heart failure, hepatic, renal or metabolic disease). - Prior therapy with systemic anti-tumour therapy with HER1/EGFR inhibitors (as small molecule or monoclonal antibody therapy). - Any other malignancies within 5 years that to the clinician s opinion may affect therapy outcome results - Any significant ophthalmologic abnormality, especially severe dry eye syndrome, keratoconjunctivitis sicca, Sjögren syndrome, severe exposure keratitis or any other disorder likely to increase the risk of corneal epithelial lesions. - Patients who cannot take oral medication, who require intravenous alimentation, have had prior surgical procedures affecting absorption, or have active peptic ulcer disease. - Nursing mothers.
Investigators
Similar Trials
Completed
Phase 2
A parallel phase II study of Tarceva®(Erlotinib) in patients with advanced non-small cell lung cancer (Stage IIIB/IV) not pre-treated by chemotherapy including dose escalation to toxicity in current and former smokers1. non-small cell lung cancersquamous cell lung malignancy10038666NL-OMON30374Hoffmann-La Roche8
Active, not recruiting
Not Applicable
A parallel phase II study of Tarceva® (Erlotinib) in patients with advanced non-small cell lung cancer (Stage IIIB/IV) not pre-treated by chemotherapy including dose escalation to toxicity in current and former smokersPatients with advanced NSCLC not previously treated with chemotherapyEUCTR2005-004782-41-DEF. Hoffmann-La Roche Ltd44
Active, not recruiting
Phase 1
A parallel phase II study of Tarceva® (Erlotinib) in patients with advanced non-small cell lung cancer (Stage IIIB/IV) not pre-treated by chemotherapy including dose escalation to toxicity in current and former smokersPatients with advanced NSCLC not previously treated with chemotherapyEUCTR2005-004782-41-GBF. Hoffmann-La Roche Ltd44
Active, not recruiting
Not Applicable
A parallel phase II study of Tarceva® (Erlotinib) in patients with advanced non-small cell lung cancer (Stage IIIB/IV) not pre-treated by chemotherapy including dose escalation to toxicity in current and former smokersPatients with advanced NSCLC not previously treated with chemotherapyMedDRA version: 8.1Level: LLTClassification code 10029521Term: Non-small cell lung cancer stage IIIBEUCTR2005-004782-41-NLF. Hoffmann-La Roche Ltd44
Active, not recruiting
Not Applicable
A parallel phase II study of Tarceva (Erlotinib) in patients with advanced non-small cell lung cancer (Stage IIIB/IV) non pre-treated by chemotherapy including dose escalation to toxicity in current and former smokers. - NDPatients with advanced NSCLC not previously treated with chemotherapyMedDRA version: 6.1Level: PTClassification code 10029521EUCTR2005-004782-41-ITROCHE44